Truist raised the firm’s price target on Gilead (GILD) to $145 from $140 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based on updated guidance for near-term launches, including BIC/LEN in 2H25, US launch of Hepcludex, and expansion opportunity for Livdelzi, and also fine-tuning its estimates for the anito-cel launch following FDA guidance, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $156 from $140 at Citi
- Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- Gilead price target raised to $155 from $145 at UBS
- Why Gilead Sciences Is Suddenly Back in the Spotlight
- Gilead announces NEJM Phase 3 study data for Trodelvy+Keytruda